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a b s t r a c t
A 47-year-old woman with Ebstein’s anomaly suffered from an out-of-hospital cardiac arrest caused by
ventricular ﬁbrillation. Electroanatomical activation mapping showed an atrialized right ventricle. Atrial
electrocardiogram, normal atrioventricular node conduction delay, and ventricular electrocardiogram
were conﬁrmed in the right atrium. Relatively preserved ventricular amplitude was found in the septal
wall. Based on these ﬁndings, a transvenous dual-chamber implantable cardioverter-deﬁbrillator was
implanted for the prevention of sudden cardiac death. The patient has fared well, without any lead
malfunctions, lead dislodgement, or inappropriate shocks. Sufﬁciently high atrial and ventricular
amplitudes were conﬁrmed during 18 months of follow-up.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Case report
A 47-year-old woman (height: 165 cm, weight: 52.8 kg) was
transported to the hospital following syncope. According to the
automated external deﬁbrillator, she experienced ventricular
ﬁbrillation (VF), which was treated with a direct current shock.
The patient had a history of cardiac surgery for an atrial septal
defect in childhood. Echocardiography and cardiac computed
tomography (Fig. 1A) revealed a severely dilated right atrium
and right ventricle, and Ebstein’s anomaly of the tricuspid valve.
On the other hand, the size and contraction of the left ventricle
were almost normal (left ventricular ejection fraction, 57%) and
her B-type natriuretic peptide level was 63.7 pg/mL. Amiodarone
(200 mg/day) and carvedilol (10 mg/day) were administered to
prevent lethal ventricular arrhythmia. Initially, electrophysiologi-
cal testing and cardiac catheterization were performed to identify
the substrate of VF and to investigate the appropriate site for the
positioning of an implantable cardioverter-deﬁbrillator (ICD) lead.
Coronary angiography revealed no signiﬁcant stenosis in the
coronary arteries. Left ventriculography showed normal wall
motion in the left ventricle. Consistent with the echocardiographic
ﬁndings, right atriography showed a signiﬁcantly dilated right
atrium and displacement of the tricuspid valve (Fig. 1B). Ventri-
cular tachyarrhythmia was not induced by a programmed
stimulation with up to three extrastimuli. Electroanatomical acti-
vation mapping (CARTOs system, Biosense Webster, Diamond Bar,
CA, USA) clearly showed an atrialized right ventricle (Fig. 2A).
Atrial electrocardiogram [Fig. 2A-(1)], normal atrioventricular
node conduction delay [Fig. 2A-(2)], and ventricular electrocardio-
gram [Fig. 2A-(3)] were conﬁrmed in the right atrium. Both atrial
and ventricular potentials were observed near the atrioventricular
groove [Fig. 2A-(2)]. At the border of the anatomical RA and
atrialized RV, the ventricular potential was deﬁned as the local
activation potential. Even though electroanatomical voltage map-
ping showed a wide low amplitude area, especially around the
atrialized ventricle, the electrograms at the septal site were
relatively preserved and were recognized as an optimal lesion
for ICD lead implantation (Fig. 2B). Based on these ﬁndings, a
transvenous dual-chamber ICD (TELIGEN 100 F111, Boston Scien-
tiﬁc Inc., St. Paul, MN, USA) was implanted for the prevention of
sudden cardiac death. The atrial lead (DEXTRUS 4136/53 cm,
Boston Scientiﬁc Inc.) and ICD lead (ENDOTAK RELIANCE G 0296/
64 cm, Boston Scientiﬁc Inc.) were successfully implanted
(Fig. 2C). P-wave and R-wave sensing was satisfactory at 3.2 mV
and 9.5 mV, respectively. Adequate capture threshold values were
measured at the right atrium (pacing threshold: 0.5 V, 0.4 ms) and
right ventricle (pacing threshold: 0.5 V, 0.4 ms). Induced ventri-
cular ﬁbrillation was successfully terminated by a 9 J direct current
shock.
The patient has fared well, without any lead malfunctions, lead
dislodgement, or inappropriate shocks. Follow-up echocardiogra-
phy showed no aggravation of tricuspid regurgitation. Sufﬁciently
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high atrial and ventricular amplitudes (P-wave: 3.5 mV and
R-wave: 9.9 mV) were conﬁrmed during 18 months of follow-up.
2. Discussion
Because of signiﬁcant progress in pediatric cardiac care, a
growing number of patients with congenital heart disease survive
well into adulthood [1,2]. The management of arrhythmia in adult
patients with congenital heart disease represents an important
issue for cardiologists [3–5]. Ebstein’s anomaly is characterized by
apical displacement of the septal and posterior leaﬂets of the
tricuspid valve. Approximately 25% of these patients have asso-
ciated accessory pathways and are at risk of supraventricular
tachycardia. Unless atrial ﬁbrillation degenerates into ventricular
ﬁbrillation in patients with manifest accessory pathways, ventri-
cular arrhythmia is a rare complication of Ebstein’s anomaly [6]. In
a multicenter cohort study, ventricular arrhythmia occurred in
only 1 of 77 young patients with Ebstein’s anomaly who received
an ICD [7]. In our case, electroanatomical voltage mapping found a
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Fig. 1. (A) Cardiac computed tomography and (B) right atriography. White arrows and white arrowheads indicate the displaced septal leaﬂet and enlarged anterior leaﬂet of
the tricuspid valve, respectively. A functional right ventricle (RV) existed between the dotted lines. The black arrowhead indicates the atrioventricular groove. LA, left atrium;
LV, left ventricle; RA, right atrium; RAO, right anterior oblique.
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Fig. 2. (A) Electroanatomical activation mapping. The green arrowheads indicate the displaced septal leaﬂet of the tricuspid valve, conﬁrmed by transthoracic
echocardiography. Electroanatomical activation mapping demonstrated the atrialized right ventricle. Atrial electrocardiogram (1), normal atrioventricular node conduction
delay (2), and ventricular electrocardiogram (3) were conﬁrmed in the right atrium. Both atrial and ventricular potentials were observed near the atrioventricular groove (2).
An enlarged anterior leaﬂet of the tricuspid valve (yellow arrowheads) existed in this patient, and therefore, it was impossible to advance a catheter and shock lead near the
apex. A, atrial potential; RA, right atrium; RV, right ventricle; V, ventricular potential. (B) Electroanatomical voltage mapping. Relatively preserved ventricular amplitude was
found in the septal wall. (C) Posterior-anterior chest X-ray after transvenous implantation of an implantable cardioverter-deﬁbrillator.
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wide low amplitude area around the atrialized ventricle. Although
ventricular tachyarrhythmia was not induced by programmed
stimulation, this low voltage area may be associated with an
arrhythmogenic region in this patient. Lacking a histological
investigation, we could not specify the pathological mechanism
underlying these electrophysiological changes.
Implantation of the device in this patient was technically
challenging because of the unusual orientation of the right
ventricle. Electroanatomical mapping can be used to determine
the exact intracardiac anatomy and conﬁrm the amplitude of the
cardiac chambers, especially in patients with complex cardiac
anatomy [8,9]. In the present case, prior electroanatomical
information was helpful in planning the transvenous procedure
strategy. Therefore, we believe that electroanatomical mapping is a
useful, minimally invasive strategy to be performed prior to the
implantation of devices in patients with a complex cardiac
anatomy. We selected the thinnest ICD device (TELIGEN 100
F111, Boston Scientiﬁc Inc.) because the size of the patient’s body
was quite small, and her precordial subcutaneous fatty layer was
assumed to be relatively thinner. The Guidant ICD lead (a shock
lead) is an integrated bipolar system, and consequently, we should
pay close attention to avoiding atrial oversensing, especially when
deep insertion of the shock lead is impossible. Although we could
not advance the lead into the apical site, probably because of an
enlarged anterior leaﬂet of the tricuspid valve, atrial double
sensing was never observed during the implantation procedures.
We successfully visualized the atrialized right ventricle and
implanted a transvenous ICD, without any complications, in a
patient who had not undergone surgery for Ebstein’s anomaly.
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